** Contract research firm Charles River Laboratories' CRL.N shares rise 3.7% to $160.12
** Reports Q4 adj profit of $2.66 per share, beating analysts' average estimate of $2.53 per share - LSEG
** Co posts Q4 sales of $1 billion, beating estimates of $983.6 million
** Expects 2025 reported revenue to decline between 4.5% and 7.5%
** Co expects biotechnology demand to be "stable to slightly improved" this year
** Co also forecast 2025 adj profit in the range of $9.10 per share to $9.60 per share, the mid-point falling below analysts' estimates of $9.57 per share
** All in, while these results are not pretty, they are likely better than worst-case fears - brokerage Evercore ISI
** Stock fell 21.9% in 2024
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.